echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > NICE supports AbbVie's Rinvoq treatment for rheumatoid arthritis

    NICE supports AbbVie's Rinvoq treatment for rheumatoid arthritis

    • Last Update: 2021-03-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    THE National Institute for Health and Care Excellence (NICE) has recommended AbbVie's Upadacitinib to patients with severe active rheumatoid arthritis (RA).NICE guidelines recommend that AbbVie's JAK inhibitors be used in combination with methotrexate in patients with severe active RA if their disease is not responding enough to the drug or is insensitive to at least two conventional disease-changing anti-rheumatoid drugs.Currently, around 400,000 people in the UK suffer from
    activity rheumatoid arthritis
    , an autoimmune disease whose immune system attacks the endometrium of the joints. This can lead to inflammation and symptoms such as pain, fatigue and stiffness.Rheumatoid arthritis is a complex autoimmune disease that can affect people in different ways. So treatment can't be a one-of-a-kind approach," said Clare Jacklin, chief executive of the National Rheumatoid Arthritis Association (NRAS).She added: "It is vital that physicians have a range of drugs available to enable them to tailor treatment options to the patient's disease type and continue to invest in research and innovative drugs for
    activity rheumatoid arthritis
    ." TheNICE guidelines allow patients to use Rinvoq, while cost-effectiveness agencies continue to evaluate the drug for treatment with moderate active RA through a separate single technical assessment (STA).We are pleased that the Committee has recognized the value that Rinvoq can bring to people with severe
    and active rheumatoid arthritis
    of the disease. We remain committed to working with NICE, which has now been interpreted as a separate
    single technical assessment in the treatment of moderate
    activity rheumatoid arthritis . Belinda Byrne, medical director of AbbVie UK, said.She added: "We are optimistic that we can also make positive claims decisions for those patients with serious illnesses who currently have limited treatment options." (cyy123.com)
    : NICE backs AbbVie's Rinvoq for severe active rheumatoid arthritis
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.